Investigational drug · Phase 3
QRX003
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Netherton Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "QRX003"
First trial start
2023
Mar 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QRX003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Netherton Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "QRX003" as an intervention, largest first.
- Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingActive, not recruiting
Quoin PharmaceuticalsIndustry
NCT05521438 · 30 participants (planned) · Start Jun 23, 2022 · Primary completion Dec 30, 2025
Drug: QRX003-2% Lotion; QRX003-4% Lotion QAM and 2 more · For: Netherton Syndrome
Sites: San Diego, California; Indianapolis, Indiana; Quincy, Massachusetts · 5 sites in all
- Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT05789056 · 20 participants (planned) · Start Mar 14, 2023 · Primary completion Dec 30, 2026
Drug: QRX003, 4% Lotion · For: Netherton Syndrome
Sites: San Diego, California; Indianapolis, Indiana; Quincy, Massachusetts · 4 sites in all
- Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT07538583 · 16 participants (planned) · Start Mar 19, 2026 · Primary completion Jan 31, 2027
Drug: QRX003 · For: Netherton Syndrome
Sites: Fremont, California; New Haven, Connecticut; Indianapolis, Indiana · 8 sites in all
- Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT06953466 · 8 participants (planned) · Start Oct 6, 2025 · Primary completion Dec 30, 2026
Drug: QRX003, 4% Lotion · For: Netherton Syndrome
Sites: Chicago, Illinois
Newest research
PubMed records naming it or its code names, newest first.
- An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and A Pediatric Compassionate-Use Case Report.
Irvine AD, Hovnanian A, Myers M, et al. · Dermatol Ther (Heidelb) 2026
Also in development for Netherton Syndrome
- SXR1096Phase 21 trial
Sixera Pharma · Netherton Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.